As reported in Fierce Biotech, Roche has decided to cut its losses and kill the taspoglutide development program. The drug experienced a publicized late stage failure last year. Roche's decision to cut the program leaves its development partner Ipsen with a 500 M euro bill for the costs of phase III development and trials. OUCH! Ipsen may be tempted to engage in a last ditch effort to save the drug -- although analysts believe this to be unlikley.
Time for that spoonful of sugar.
Posted by Bruce Lehr Feb 1st 2011.